ReviewJournal of neural transmission (Vienna, Austria : 1996)2015
Polypharmacy in the treatment of subjects with intellectual disability.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Effectiveness of medication reviews in identifying and reducing medication-related problems among people with intellectual disabilities: A systematic review.Journal of applied research in intellectual disabilities : JARID · 2019Pooled it
- A Rapid Mapping Review of Medication Burden in Adults with an Intellectual Disability: What We Know and What We Do Not Know.Drug, healthcare and patient safety · 2026Review
- Clinical audit of psychotropic medication use at a South African intellectual disability hospital.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2026Article
- Value of a web-based pediatric drug information system to prevent serious adverse drug reactions in child and adolescent psychiatry.Journal of neural transmission (Vienna, Austria : 1996) · 2023Article
- Special Considerations for Management of Diabetes in Adult Patients with Intellectual and Developmental Disabilities.Advances in medicine · 2023Review
- Community-Based Support and Social Services and Their Association with Frailty Factors in Older People with Intellectual Disability and Affective and Anxiety Disorders: A Swedish National Population-Based Register Study.Community mental health journal · 2022Article
- TOP-ID: a Delphi technique-guided development of a prescription and deprescription tool for adults with intellectual disabilities.BMJ open · 2020Article
- Article
- Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.Therapeutic advances in drug safety · 2018Review
- Article
- Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.BMC psychiatry · 2016Observational
- Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability.Drugs & aging · 2015Review
- Assessing the Impact of Psychotropic Medication Changes on Challenging Behavior of Individuals with Intellectual Disabilities.International journal of developmental disabilitiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with intellectual disabilities often suffer from mental disorders or display challenging behavior. For both impairments, treatment with more than one psychopharmacological drug is common, although little is known about efficacy and side effects of polypharmacological treatment. The paper reviews studies on treatment of people with intellectual disability (ID) with more than one psychoactive drug. Many studies rely on poor evidence and are supplemented with data from our own research. Risks and benefits of different combinations containing neuroleptics are listed. Ethical considerations for the use of different drugs combined are discussed. The use of combinations of neuroleptics on people with ID should be carried out with great care, since side effects may be amplified in people with ID, depending on the combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.